Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-10-31
2010-02-16
Graser, Jennifer E (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C435S007220, C435S007920, C435S004000
Reexamination Certificate
active
07662575
ABSTRACT:
This invention discloses methods for identifyingFrancisella tularensisvaccine candidates. It enables identification of novel vaccine candidates and quality assurance for vaccine batches, assessment of protection in vaccinates and identification of the infecting agent in vaccinates. Mice were first vaccinated withBrucella abortusO-polysaccharide (OPS) vaccine. These animals were then given 10 LD50s ofF. tularensislive vaccine strain (LVS). Sixty percent (60%) of the vaccinated mice survived the multiple lethal doses. Sera were collected from these surviving mice and the antibodies were used to probe supernatant and cell lysates of liveF. tularensisLVS cultures. SeveralF. tularensiscomponents were identified only by the noted “survivor” antisera. Of these identified proteins, enzyme digestions and chemical oxidation suggest post-translational modifications of some proteins e.g. a 52 kDa glycoprotein, a 45 kDa lipoprotein and a 19 kDa nucleoprotein. The 52 kDa component caused nitrous oxide induction in tissue cultures at low concentrations, cell death at high concentrations. Vaccination with this gave partial protection while addition of other components acted synergistically to give enhanced protection from 250 LD50s ofF. tularensisLVS.
REFERENCES:
Stewart,Francisella, Chapter 43, Manual of Clinical Microbiology, Fifth Edition, pp. 454-456, Nov. 1997.
Franz et al, Clinical Recognition and Management of Patients Exposed to Biological Warfare Agents, JAM, Aug. 6, 1997, vol. 278, No. 5, pp. 399-411.
Evans et al, Tularemia, Chapter 24, Medical Aspects of Chemical and Biological Warfare, pp. 504-512, 1995.
Cherwonogrodzky et al, Increased encapsulation and virulence ofFrancisella tularensislive vaccine strain (LVS) by subculturing on synthetic medium, Vaccine 1994, vol. 12, No. 9, pp. 773-775.
Corbel, Recent Advances in the Study of Brucella Antigens and their Serological Cross-Reactions, Veterinary Bulletin, Commonwealth Agricultural Bureaux, Dec. 1985, vol. 55, No. 12, pp. 927-942.
Abstracts, 4. Medizinische B-Schutz-Tagung des BMVg, am 22. und 23. Oct. 1997.
Golovliov et al, Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogenFrancisella tularensis, Vaccine, 1995, vol. 13, No. 3, pp. 251-267.
Hood, Virulence factors ofFrancisella tularensis, Journal of Hygiene, 1977, vol. 79, No. 1, pp. 47-60 (with 5 plates).
Ancuta et al, Inability of theFrancisella tularensisLipopolysaccharide to Mimic or to Antagonize the Induction of Cell Activation by Endotoxins, Inspection and Immunity, Jun. 1996, vol. 64, No. 6, pp. 2041-2046.
Conlan et al, Mice vaccinated with theO-antigen ofFrancisella tularensisLVS lipopolysaccharide conjugated to bovine serum alburnin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen, Vaccine 20 (2002), pp. 3465-3471.
Cherwonogrodzky, Factors Controlling Haemolysin Production inVibrio Parahaemolyticus, 1983, pp. 161-162.
Berger Bradley
Cherwonogrodzky John
Sikora Christopher
Graser Jennifer E
Her Majesty the Queen in right of Canada as represented by the
Nixon & Vanderhye P.C.
LandOfFree
Use of cross-protection to identify novel vaccine candidates... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of cross-protection to identify novel vaccine candidates..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of cross-protection to identify novel vaccine candidates... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4188134